Stocks Health care PRAX
NASDAQ · Health carePraxis Precision Medicines, Inc. (PRAX)
It posted a net loss of $359.4M. In fiscal 2025 capital spending exceeded operating cash flow by $249.1M. At September 30, 2026 it held $361.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Praxis Precision Medicines, Inc.
- Net worth
- Praxis Precision Medicines, Inc. has a market value (market cap) of $9.4B at the latest share price, and shareholders' equity of $1.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $303.3M.
- Cash flow
- In fiscal 2025 operations used $249.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Praxis Precision Medicines, Inc.'s next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Praxis Precision Medicines, Inc. does
Praxis Precision Medicines, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PRAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$303.3M | -$13.48 | -$249.1M |
| 2024 | $8.6M | -$182.8M | -$10.21 | -$131.8M |
| 2023 | $2.4M | -$123.3M | -$18.69 | -$111.2M |
| 2022 | $0 | -$214M | -$69.65 | -$185.5M |
| 2021 | n/a | -$167.1M | -$59.14 | -$125.6M |
| 2020 | n/a | -$61.8M | -$117.98 | -$52.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Praxis Precision Medicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 7, 2026Other event 8-K
- July 2, 2026Auditor change 8-K
- June 29, 2026Other event 8-K
- June 22, 2026Other event 8-K
Insider trades
What the people running Praxis Precision Medicines, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 8, 2026 | Souza MarcioChief Executive Officer, Director | Gave as a gift | 20,521 | - |
| July 8, 2026 | Souza MarcioChief Executive Officer, Director | Gave as a giftindirect | 2,600 | - |
| June 24, 2026 | DeSimone JillDirector | Exercised options | 8,566 | $379K |
| June 24, 2026 | DeSimone JillDirector | Exercised options | 3,034 | $446.9K |
| June 24, 2026 | DeSimone JillDirector | Soldpre-planned (10b5-1) | 10 | $3K |
| June 24, 2026 | DeSimone JillDirector | Soldpre-planned (10b5-1) | 120 | $36.4K |
| June 24, 2026 | DeSimone JillDirector | Soldpre-planned (10b5-1) | 320 | $97.7K |
| June 24, 2026 | DeSimone JillDirector | Soldpre-planned (10b5-1) | 683 | $209.5K |
Who owns PRAX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive with 1 related filers | 12.3% | November 14, 2025 |
| Steven A. Cohen13G, passive with 5 related filers | 9.6% | November 14, 2024 |
| Fmr LLC13G, passive with 1 related filers | 7.7% | May 6, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 7.2% | February 17, 2026 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 6.3% | May 15, 2026 |
| Orbis Investment Management Ltd13G, passive with 1 related filers | 5.5% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 309 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 3,421,374 | new |
| Fmr LLC | 2,316,907 | +155,964 |
| BlackRock, Inc. | 2,292,585 | -32,344 |
| Perceptive Advisors LLC | 2,035,986 | 0 |
| Baker Bros. Advisors LP | 1,753,198 | 0 |
| Orbis Allan Gray Ltd | 1,529,788 | -942,692 |
| Vanguard Portfolio Management LLC | 1,335,185 | +578,437 |
| Vanguard Capital Management LLC | 1,235,299 | +13,355 |
| State Street Corp | 1,026,443 | +142,205 |
| Adage Capital Partners GP, L.L.C. | 1,015,480 | +199,741 |
| Deerfield Management Company, L.P. | 963,351 | 0 |
| Driehaus Capital Management LLC | 959,048 | +9,823 |
| Morgan Stanley | 854,112 | +20,621 |
| Geode Capital Management, LLC | 748,039 | +97,135 |
| Cormorant Asset Management, LP | 640,000 | -245,500 |
| Goldman Sachs Group Inc | 548,830 | -161,904 |
| Bank of America Corp | 546,930 | +12,326 |
| Invesco Ltd. | 537,548 | +476,151 |
| Hood River Capital Management LLC | 425,167 | +66,549 |
| Norges Bank | 346,969 | new |
Insiders
13 insiders reported holding 189,512 shares in total, about $64M at the last price.
| Holder | Shares |
|---|---|
| Souza MarcioChief Executive Officer, Director | 56,495 |
| Kelly Timothy EdwinChief Financial Officer | 31,167 |
| Sniecinski MeganChief Operating Officer | 28,664 |
| Nemiroff AlexGeneral Counsel and Secretary | 26,011 |
| Mitchell Dean JDirector | 18,622 |
| Mastrocola LaurenPrincipal Accounting Officer | 13,573 |
| Young William DDirector | 3,269 |
| Kindler Jeffrey BDirector | 2,537 |
| Arbuckle Stuart ADirector | 2,537 |
| DeSimone JillDirector | 2,337 |
Questions about PRAX
What does Praxis Precision Medicines, Inc. do?
Praxis Precision Medicines, Inc. is a company in the Health care sector, listed on NASDAQ as PRAX. Its shares trade on NASDAQ under the ticker PRAX.
What is Praxis Precision Medicines, Inc.'s net worth?
Praxis Precision Medicines, Inc. has a market value (market cap) of $9.4B at the latest share price, and shareholders' equity of $1.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Praxis Precision Medicines, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $359.4M.
When did Praxis Precision Medicines, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Praxis Precision Medicines, Inc.'s next earnings report?
Praxis Precision Medicines, Inc.'s next report is expected around January 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PRAX with
Follow PRAX
Get an email when Praxis Precision Medicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Praxis Precision Medicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.